

Acetylsalicylic acid**Section**

Medicines for juvenile joint diseases

- Local > Rectal > Suppository: 150 mg; 300 mg
- Oral > Solid > dispersible tablet: 75 mg; 300 mg; 500 mg
- Oral > Solid > tablet: 75 to 500 mg

Indications

Acute rheumatic fever without mention of heart involvement

Mucocutaneous lymph node syndrome

Juvenile idiopathic arthritis

Adalimumab**Section**

Medicines for juvenile joint diseases

- Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL

Indications

Juvenile idiopathic arthritis

Allopurinol**Section**

Medicines used to treat gout

- Oral > Solid: 100 mg

Indications

Gout

Anakinra**Section**

Medicines for juvenile joint diseases

- Parenteral > General injections > SC: 100 mg per 0.67 mL in pre-filled syringe

Indications

Juvenile systemic arthritis

Azathioprine**Section**

Disease-modifying anti-rheumatic drugs (DMARDs)

- Oral > Solid > tablet: 50 mg (scored)

Indications

Rheumatoid arthritis, serology unspecified

Psoriatic arthritis

Certolizumab pegol**Section**

Medicines for juvenile joint diseases

IndicationsTherapeutic equivalent to [adalimumab](#) for

Juvenile idiopathic arthritis

Chloroquine

Section

Disease-modifying anti-rheumatic drugs (DMARDs)

- Oral > Solid: 100 mg tablet (as phosphate or sulfate); 150 mg tablet (as phosphate or sulfate)

Indications

Rheumatoid arthritis

Colchicine

Section

Medicines used to treat gout

- Oral > Solid: 0.5 mg

Indications

Gout

Etanercept

Section

Medicines for juvenile joint diseases

Indications

Therapeutic equivalent to [adalimumab](#) for

Juvenile idiopathic arthritis

Golimumab

Section

Medicines for juvenile joint diseases

Indications

Therapeutic equivalent to [adalimumab](#) for

Juvenile idiopathic arthritis

Hydroxychloroquine

Section

Disease-modifying anti-rheumatic drugs (DMARDs)

- Oral > Solid: 200 mg (as sulfate)

Indications

Systemic lupus erythematosus

Cutaneous lupus erythematosus of unspecified type

Infliximab

Section

Medicines for juvenile joint diseases

Indications

Therapeutic equivalent to [adalimumab](#) for

Juvenile idiopathic arthritis

Methotrexate

Section

Disease-modifying anti-rheumatic drugs (DMARDs)

- Oral > Solid > tablet: 2.5 mg (as sodium salt)

Medicines for juvenile joint diseases

- Oral > Solid > tablet: 2.5 mg (as sodium salt)

Indications

Rheumatoid arthritis, serology unspecified

Juvenile idiopathic arthritis

Penicillamine

Section

Disease-modifying anti-rheumatic drugs (DMARDs)

- Oral > Solid: 250 mg

Indications

Rheumatoid arthritis, serology unspecified

Probenecid

Section

Medicines used to treat gout

- Oral > Solid: 500 mg

Indications

Gout

Sulfasalazine

Section

Disease-modifying anti-rheumatic drugs (DMARDs)

- Oral > Solid: 500 mg

Indications

Rheumatoid arthritis, serology unspecified

Tocilizumab

Section

Medicines for juvenile joint diseases

- Parenteral > General injections > IV: 80 mg per 4 mL in vial; 200 mg per 10 mL in vial; 400 mg per 20 mL in vial
- Parenteral > General injections > SC: 162 mg per 0.9 mL in pre-filled syringe

Indications

Juvenile systemic arthritis

Triamcinolone hexacetonide

Section

Medicines for juvenile joint diseases

- Parenteral > Locoregional injections > Intra-articular: 20 mg per mL in vial

Indications

Juvenile idiopathic arthritis